title: SARS: ventilatory and intensive care.
abstract: Severe acute respiratory syndrome (SARS) is an emerging infection caused by a novel coronavirus. It is characterised by a highly infectious syndrome of fever and respiratory symptoms, and is usually associated with bilateral lung infiltrates. The clinical syndrome of SARS often progresses to varying degrees of respiratory failure, with about 20% of patients requiring intensive care. Despite concern about potential aerosol generation, non-invasive ventilation (NIV) has been reported to be efficacious in the treatment of SARS-related ARF without posing infection risks to health care workers (HCW). Spontaneous pneumomediastinum and pneumothorax in SARS is common. The incidence of NIV-associated barotrauma ranged from 6.6% to 15%. Patients who fail to tolerate NIV or fail NIV with progressive dyspnoea, tachypnoea and hypoxaemia should be intubated and mechanically ventilated. Mortality rates in intensive care units for SARS patients were high: 34-53% at 28 days, when some patients were still being ventilated. Strict adherence to infection control measures including isolation, use of appropriate personal protective equipment and negative pressure environment had been reported to eliminate cross-infection to HCW.
authors.affiliation: Department of Medicine, Pamela Youde Nethersole Eastern Hospital, Hong Kong SAR, China. lycyam@ha.org.hk
authors.forename: Loretta Y C
authors.initials: LY
authors.lastname: Yam
authors.forename: Rong Chang
authors.initials: RC
authors.lastname: Chen
authors.forename: Nan Shan
authors.initials: NS
authors.lastname: Zhong
mesh_terms: D003422:Critical Care / Q000379:methods*; D006801:Humans; D017053:Infection Control / Q000379:methods*; D007362:Intensive Care Units; D011175:Positive-Pressure Respiration / Q000379:methods*; D045169:Severe Acute Respiratory Syndrome / Q000188:drug therapy / Q000628:therapy*